Results 201 to 210 of about 843,559 (297)

Management of chronic urticaria: Current status and future prospect

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman   +15 more
wiley   +1 more source

A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies. [PDF]

open access: yesBlood Adv
Watanabe T   +9 more
europepmc   +1 more source

Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley   +1 more source

B-cell modulators in immunoglobulin A nephropathy. [PDF]

open access: yesFront Immunol
Rajasekaran A, Novak J, Rizk DV.
europepmc   +1 more source

Physical Activity, Bleeding Incidence and Health‐Related Quality of Life, in Patients With Haemophilia A Without Inhibitors, Treated With Emicizumab: A Post‐Hoc Descriptive Analysis of the Power Study Data

open access: yes
Haemophilia, EarlyView.
Matteo Nicola Dario Di Minno   +7 more
wiley   +1 more source

Efficacy and Safety of Risankizumab Among Patients With Ulcerative Colitis in East Asia: A Post Hoc Analysis of Two Randomized Clinical Trials

open access: yesJournal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim Risankizumab, a monoclonal interleukin 23p19 antibody, is a treatment for ulcerative colitis. This post hoc analysis reports the efficacy and safety of risankizumab for ulcerative colitis in patients in East Asia from the global phase 3 clinical trials. Methods In the 12‐week, phase 2b/3 induction study (NCT03398148), adults
Ken Takeuchi   +14 more
wiley   +1 more source

Periodontitis and rheumatoid arthritis—Global efforts to untangle two complex diseases

open access: yesPeriodontology 2000, EarlyView.
Abstract Understanding the impact of oral health on rheumatoid arthritis (RA) will inform how best to manage patients with both periodontitis and RA. This review seeks to provide an update on interventional and mechanistic investigations, including a brief summary of European Research programs investigating the link between periodontitis and RA. Recent
Isabel Lopez‐Oliva   +2 more
wiley   +1 more source

A functionally distinct HPA‐1a‐specific alloantibody associated with fetal/neonatal alloimmune thrombocytopenia that activates platelets via FcγRIIa

open access: yesTransfusion, EarlyView.
Abstract Background Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is caused by maternal alloantibodies directed against fetal platelet antigens, most commonly human platelet antigen‐1a (HPA‐1a). These antibodies mediate platelet destruction and can lead to fetal and neonatal thrombocytopenia severe enough to cause life‐threatening organ bleeds ...
Huiying Zhi   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy